Boosting its chances of being first to market a drug in that setting, Roche on March 20 reported positive progression-free survival (PFS) headline data from the IMpower131study evaluating its PD-L1 inhibitor Tecentriq (atezolizumab) in first-line squamous cell lung cancer.
But whether Roche can keep that lead will only become clear when data from the program matures on overall survival...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)